Trials / Completed
CompletedNCT04083820
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)
A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 521 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | semaglutide | Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion. |
Timeline
- Start date
- 2019-09-16
- Primary completion
- 2021-09-27
- Completion
- 2021-09-27
- First posted
- 2019-09-10
- Last updated
- 2023-03-28
Locations
53 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04083820. Inclusion in this directory is not an endorsement.